Today Topics

Confirmed: Primary endpoint of significantly improving overall survival not met Merck Serono, a division of Merck, Darmstadt, Germany, today announced detailed results from the randomized Phase III START* trial of its investigational MUC1 antigen-specific cancer immunotherapy L-BLP25 (formerly referred to as Stimuvax) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC). [...]

A clinical trial has shown that patients, and their physicians, are eager to jump into next-era cancer care – analysis of an individual’s tumor to find and target genetic mutations that drive the cancer. Results of the study, CUSTOM, are being presented at the 2013 annual meeting of the American Society of Clinical Oncology* years [...]

Licensing agreement allows development of a novel combination therapeutic for non-small-cell lung carcinoma, a type of lung cancer difficult to treat with conventional chemotherapy. The University of Colorado (CU) has signed an exclusive, worldwide licensing agreement with Syndax Pharmaceuticals, a company focused on the development of novel combination strategies for cancers that have become resistant [...]

Lung cancer is associated with very high mortality, in part because it is hard to detect at early stages, but also because it can recur frequently after surgical removal. The question arises as to what is the best way to follow lung cancer patients after surgery in order to spot problems early enough, before symptoms [...]

Researcher Hopes to Screen Smokers with Early Stage Lung Disease in Next Research Phase An internist and instructor at Ben-Gurion University of the Negev has conducted research proving that specially trained dogs can differentiate the smell of breast cancer cells from non-cancerous cells in cell cultures. The concept of using the sniffing ability of dogs [...]